Vimarsana
Biggest News Aggregation in the World

Page 11 - Activity Research News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Activity Research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Activity Research Today - Breaking & Trending Today

Experts say digital fitness trend is likely here to stay - Vimarsana News

Experts say digital fitness trend is likely here to stay

TOLEDO, Ohio – Going to the gym was always part of Kari Hamra's routine until last year's go ...

Will gyms go the way of arcades and movie rental stores? - Vimarsana News

Will gyms go the way of arcades and movie rental stores?

Going to the gym was always part of Kari Hamra’s routine until last year’s government-ordered shutdowns forced her to replace the workouts with daily rides on her Peloton stationary bike.

Source: wcpo.com
What happens to fitness industry as more people turn to working out from home, attend virtual classes? - Vimarsana News

What happens to fitness industry as more people turn to working out from home, attend virtual classes?

Thousands of small fitness centers and studios that were forced to close a year ago now are gone for good.

Epidemiologists say CDC exaggerated outdoor covid risks -- Health & Wellness -- Sott.net - Vimarsana News

Epidemiologists say CDC exaggerated outdoor covid risks -- Health & Wellness -- Sott.net

Only about 52% of the U.S. public says they have trust in the U.S. Centers for Disease Control and Prevention, according to a recent Robert Wood Johnson Foundation/Harvard T.H. Chan School of Public Health poll.1 After the year we've just had,...

Source: sott.net
UNION therapeutics' COVID-19 candidates show promising results in phase 1 study - Vimarsana News

UNION therapeutics' COVID-19 candidates show promising results in phase 1 study

UNION therapeutics’ COVID-19 candidates show promising results in phase 1 study Apr 7 2021 UNION therapeutics A/S (UNION) announced today that the results of a phase 1 study of inhaled and intranasal niclosamide (UNI911) have been published by The Lancet Regional Health – Europe (LINK). With no serious adverse effects reported, the study showed a strong safety profile of inhaled and intranasal niclosamide which was the primary endpoint for the trial. The promising safety and pharmacokinetic results for inhaled and intranasal niclosamide have opened the doors for further investigation, and...